12.13.05Scientists Report Intermittent, Oral Dosing of the HIF-PH Inhibitor, FG-2216, Increases and Maintains Hemoglobin Levels in a Preclinical Study of Chronic Anemia
11.14.05FibroGen Provides Update on the Development of FG-2216 and FG-4592, Oral Therapies for Anemia
2.16.05FibroGen Completes Equity Financing
